Advertisement
YOU ARE HERE: LAT HomeCollectionsCardiac Science Inc
IN THE NEWS

Cardiac Science Inc

FEATURED ARTICLES
BUSINESS
August 27, 1999
The Irvine maker of cardiac devices and software posted a second-quarter loss of $1.9 million, or 24 cents a share, compared with a loss of nearly $1.1 million, or 22 cents a share, for the same period last year. No revenue was reported.
ARTICLES BY DATE
BUSINESS
August 4, 2005
* Staffing company RemedyTemp Inc. reported a net loss of $1.4 million, or 16 cents a share, for its fiscal third quarter, compared with a loss of $1.3 million, or 14 cents, a year earlier. The company, based in Aliso Viejo, posted revenue of $122.3 million, down 5% from a year earlier, for the quarter ended July 3. * Cardiac Science Inc. of Irvine posted a second-quarter net loss of $7.1 million, or 8 cents a share, compared with a loss of $5.3 million, or 7 cents, a year earlier.
Advertisement
BUSINESS
May 18, 1999
Cardiac Science Inc.: The Irvine maker of cardiac defibrillator devices and software posted a net loss of $1.2 million, or 16 cents a share, for the first quarter, compared with a net loss of $711,506, or 14 cents a share, for the first quarter of 1998. No revenue was reported.
BUSINESS
July 2, 2002 | Bloomberg News
Cardiac Science Inc. lost a bid to block rival Zoll Medical Corp. from selling heart defibrillators used in public places. U.S. District Judge Stephen Wilson in Los Angeles denied Cardiac Science's request after hearing arguments. The Irvine-based company sued in March, days after Zoll received Food and Drug Administration approval for an automated external defibrillator that can be used by trained people such as lifeguards and flight attendants.
BUSINESS
January 11, 2001 | Marc Ballon
* Cardiac Science Inc., seeking to expand its overseas presence, said it offered to acquire Artema Medical, a Swedish maker of patient monitors and defibrillators, for $20 million in stock. The Irvine-based manufacturer of external defibrillators said the deal would give it access to new customers in the Middle East, Europe and Asia. Cardiac stock closed unchanged at $5 on Nasdaq.
BUSINESS
September 26, 2001 | A Times Staff Writer
Defibrillator maker Cardiac Science Inc. said this week that shareholders have approved the Irvine company's acquisition of Survivalink Corp., a Minneapolis maker of external defibrillators, for $71 million in cash and stock. Shareholders also approved an increase in the number of authorized shares to a maximum of 100 million from 40 million, Cardiac said.
BUSINESS
September 14, 2000
Cardiac Science Inc., an Irvine developer of external cardiac defibrillator devices and software, said its common stock will begin trading today on the Nasdaq National Market System under the symbol DFIB. The shares hit a 52-week high of $9.38 Wednesday before closing at $9.25, up 88 cents, in over-the-counter trading. The stock has increased nearly 95% this year.
BUSINESS
March 14, 2001
Cardiac Science Inc. said its planned acquisition of Artema Medical, a Swedish maker of patient monitors and defibrillators, should close in the first week in June, about a month later than previously estimated. Cardiac, an Irvine manufacturer of external defibrillators, said the stock acquisition "is a relatively lengthy and complex process" because of regulatory requirements in Sweden as well as in the U.S.
BUSINESS
March 5, 1999
Irvine biomedical company Cardiac Science Inc. said Thursday it agreed to acquire HeartSine Technologies Inc., a privately held research and development firm with operations in Northern Ireland and Orange County, in a stock transaction. HeartSine's expertise and defibrillation technology will enable Cardiac Science to bring new products to market that offer cardiac arrest victims life-saving defibrillation therapy without human intervention, Cardiac said.
BUSINESS
March 29, 2002 | Bloomberg News
Cardiac Science Inc. said it filed a lawsuit accusing rival Zoll Medical Corp. of stealing its patented ideas for heart defibrillators. Zoll said Tuesday it received Food and Drug Administration approval for an automated external defibrillator that can be used by people such as lifeguards, flight attendants and security guards. Cardiac Science claims Zoll's new defibrillator uses technology covered by two Cardiac Science patents.
BUSINESS
September 26, 2001 | A Times Staff Writer
Defibrillator maker Cardiac Science Inc. said this week that shareholders have approved the Irvine company's acquisition of Survivalink Corp., a Minneapolis maker of external defibrillators, for $71 million in cash and stock. Shareholders also approved an increase in the number of authorized shares to a maximum of 100 million from 40 million, Cardiac said.
BUSINESS
June 15, 2001 | Marc Ballon
Cardiac Science Inc. said Thursday that continued reviews by federal regulators have delayed for a third time its plans to acquire a Swedish maker of patient monitors and defibrillators. The struggling Irvine maker of defibrillators said in a news release that the pending $20-million stock swap to purchase Artema Medical AB was delayed "to satisfy U.S. regulatory requirements." Cardiac, whose accountants raised doubts in February about its ability to survive, has been trying to raise money.
BUSINESS
April 17, 2001 | Dow Jones
Cardiac Science Inc., an Irvine maker of external cardiac defibrillators, said Monday that Roderick de Greef has been named chief financial officer and executive vice president and two others have been appointed to key positions. The company said in a press release that it also has appointed Guy Sohie as senior vice president for operations and Prabodh Mathur as chief product development officer.
BUSINESS
April 10, 2001 | MARC BALLON
More defibrillator developments: Cardiac Science Inc. of Irvine has won Canadian regulatory approval for the Powerheart, a defibrillator worn by hospital patients to monitor heart rates and deliver jolts during cardiac arrest. With a population of about 30 million, Canada is a good market for Cardiac, Chief Executive Raymond W. Cohen said. The Powerheart is now available in 32 countries, including the Czech Republic and Australia.
BUSINESS
April 10, 2001
Cardiac Science Inc., an Irvine maker of defibrillator devices and monitoring software, reported a fourth-quarter net loss of nearly $7.4 million, or 30 cents a share, up from $2.9 million, or 25 cents per share, a year earlier. Sales rose to about $1.5 million from $103,000. For the year, Cardiac lost $32.9 million, or $1.82 per share, compared with $7.7 million, or 85 cents per share, in 1999. The most recent loss included noncash charges of $16.
Los Angeles Times Articles
|